TAMPA, Fla.--(BUSINESS WIRE)--Verséa Discovery, Inc., a Florida-based company dedicated to advancing scientific research and development in the area of personalized and precision medicine, has announced the official launch of mescreen™ Research Validator.
The mescreen™ Research Validator is a groundbreaking, proprietary compound assessment platform that harnesses mitochondrial function and dynamics to generate critical data, supporting the development, formulation, and clinical validation of customers' supplements, nutraceuticals, pharmaceuticals, biologics, and medical devices.
By utilizing patented optimized bioassay, imaging, and machine-learning process, the mescreen™ Research Validator delivers valuable insights into mitochondrial efficiency and the clinical effects of various test materials in-vitro and in-vivo.
Research utilizing Verséa's proprietary machine learning system has analyzed over 60 FDA-approved compounds and probes known to impact mitochondrial function and dynamics. These studies have demonstrated the platform's capability to detect changes in mitochondrial function and structure upon the introduction of test materials into the assay. The platform is also able to detect changes in mitochondrial function when therapeutics, interventions and lifestyle changes were introduced to and implemented by subjects.
"We are thrilled to bring this groundbreaking technology to market," said Stephen Porada, the President of Verséa Discovery, Inc. "mescreen™ Research Validator has tremendous potential to help companies validate or optimize the performance of their bioactive molecules, ingredients or physical interventions being targeted for commercial product development."
Dr. Hemal Patel, Chief Scientific Advisor of Verséa Discovery, Inc., added, "In addition to this important advancement, we are currently developing the mescreen™ Personalized Mitochondrial Efficiency Test, which aims to provide individuals with a comprehensive energetic profile. This test will utilize a 12-matrix panel to accurately quantify core functions and dynamics providing important data and information related to one’s mitochondrial efficiency. Our commitment to enhancing mitochondrial health will empower individuals to better understand and improve their well-being."
To gain insight into the science behind mescreen™ Research Validator and explore how it can benefit your research and product development efforts, please contact Verséa Discovery, Inc. at discovery@versea.com or call 1-800-397-0670.
About Verséa Discovery, Inc.
Verséa Discovery, Inc., headquartered in Tampa, FL, is a U.S. company committed to advancing scientific research and development in personalized and precision medicine. Operating as a strategic business unit of Verséa Health, Inc., the company specializes in developing innovative solutions that deliver critical insights into health at the cellular and mitochondrial levels. To learn more visit Verséa Discovery webpage.
Disclaimer: mescreen™ is for research use only and is not intended to diagnose, treat, or cure disease. You should not change medications, diet, exercise regimens, or other related health activities without consulting your physician. mescreen™ has not been reviewed by the Food and Drug Administration. mescreen™ is a trademark of Verséa Health, Inc.
